Mucoscal vaccine and methods for using the same
OwnerSean Semple, Sandy Klimuk +1inventors
InventorsSean Semple, Sandy Klimuk, Zuan-Ning Yuan
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for stimulating enhanced mucosal immune responses in vivo. Particularly, the present invention relates to lipid-nucleic acids (“LNA”) formulations and methods of using thereof for stimulating enhanced mucosal immune responses in mammals. More particularly, the present invention relates to improved mucosal vaccines comprising target antigens associated with LNA formulations and methods of using thereof that stimulate antigen-specific mucosal immune responses in mammals.
Claims22
A method for stimulating an enhanced mucosal immune response in a mammal, said method comprising administering to said mammal an effective amount of an immunostimulatory composition comprising a lipid-nucleic acid (LNA) formulation associated with at least one antigen, wherein said LNA formulation comprises:
- a) a lipid component comprising at least one lipid;
- and
- b) a nucleic acid component comprising at least one oligonucleotide,
- wherein said immunostimulatory composition stimulates an increased production of IgA as compared to the free form of said at least one oligonucleotide, in vivo.
An improved mucosal adjuvant comprising a lipid-nucleic acid (LNA) formulation, said LNA formulation comprising:
- a) a lipid component comprising at least one lipid;
- and
- b) a nucleic acid component comprising at least one oligonucleotide,
- wherein said nucleic acid component is encapsulated by said lipid component, and said lipid component and said nucleic acid component act synergistically to stimulate immunoglobulin A (IgA) production in a mammal.
An improved mucosal vaccine composition comprising a lipid nucleic acid (LNA) formulation associated with at least one antigen, said LNA formulation comprising:
- a) a lipid component comprising at least one lipid;
- and
- b) a nucleic acid component comprising at least one oligonucleotide, wherein said nucleic acid component is encapsulated by said lipid component, and said lipid component and said nucleic acid component act synergistically to stimulate antigen-specific immunoglobulin A (IgA) production in a mammal.
Dependencies are inferred from the claim text.